Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / Shire plc

2018 · Acquisition/Merger · $62.0B · Complete

Takeda acquired Shire for approximately $62 billion in the largest-ever foreign acquisition by a Japanese company, gaining a leading rare disease and plasma-derived therapies portfolio and transforming into a global top-10 biopharmaceutical company with over $30 billion in combined revenue.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced May 08, 2018
• Closed Jan 08, 2019
• Deal value $62.0B
• Deal type Acquisition/Merger
• Therapeutic area Gastroenterology, Hematology, Immunology, Metabolic, Neurology, Oncology
• Indications Hereditary angioedema, Hemophilia A, Ulcerative colitis, Crohn's disease, Hunter syndrome, Gaucher disease, Primary immunodeficiency
• Key assets Adynovate/Adynovi (antihemophilic factor), Takhzyro (lanadelumab), Gammagard/Kiovig (immune globulin), Firazyr (icatibant), Vpriv (velaglucerase alfa), Elaprase (idursulfase), Replagal (agalsidase alfa), Immunoglobulin franchise, SHP647 (divested per regulatory requirement)
• Mechanism Anti-integrin monoclonal antibody, Recombinant coagulation factor VIII, Anti-kallikrein monoclonal antibody, Polyclonal immunoglobulin

← Browse all deals  ·  How we score deals